Search
Choline C 11
go.drugbank.com/drugs/DB09277ApprovedCholine C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes. … [A32041] It was developed by MCPRF and FDA first approved in September 2012.
Fibrinogen human
go.drugbank.com/drugs/DB09222ApprovedInvestigationalIt is a soluble plasma glycoprotein with a molecular weight of about 340 kDa and is a physiological substrate for three enzymes: plasmin, factor XIIIa, and thrombin. … Fibrinogen concentrate (human) is a hematological agent. It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting.
Mixtures: EVICEL® SELLANTE DE FIBRINA HUMANA, TISSEEL FIBRIN SEALANT VH S/D (FROZEN)Lipegfilgrastim
go.drugbank.com/drugs/DB13200ApprovedThe average molecular mass of lipegfilgrastim comprises 18,798 Da for [DB00099], 203 Da for GalNAc, 338 Da for glycylsialic acid and approximately 20,000 Da for PEG [L2449]. … Lipegfilgrastim is a covalent conjugate of [DB00099] with a single methoxy polyethylene glycol (PEG) molecule via a carbohydrate linker consisting of glycine, N-acetylneuraminic acid and N-acetylgalactosamine
AstraZeneca COVID-19 Vaccine
go.drugbank.com/drugs/DB15656ApprovedInvestigational[L32649,L32664] In March 2021, several EU member countries halted the administration of AstraZeneca's COVID-19 Vaccine due to signals of an increased risk of blood clots associated with thrombocytopenia … Upon review, the European Medicines Agency (EMA) determined that the vaccine was not associated with a higher overall risk of blood clots, but that it may be associated with very rare instances of blood
Categories: Vaccines, DNACapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalday. … Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades
Memantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalInitially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366
Categories: N-methyl-D-aspartate Receptor AntagonistProducts: MEMANTIN 1A PHARMA 10MG, MEMANTIN 1A PHARMA 20MGEravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalIt was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive
Categories: Monoamine Oxidase A SubstratesHistidine
go.drugbank.com/drugs/DB00117ApprovedInvestigationalNutraceuticalAn essential amino acid that is required for the production of histamine.
Synonyms: (S)-a-Amino-1H-imidazole-4-propanoic acidMixtures: SOLUCION DP-AMINE, TRAVASOL PLUS 15% LIBRE DE BISULFITOGaboxadol
go.drugbank.com/drugs/DB06554InvestigationalDevelopment of Gaboxadol was stopped in March 2007 after concerns regarding safety and efficacy. It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives.
Esmirtazapine
go.drugbank.com/drugs/DB06678InvestigationalMerck has terminated its internal clinical development program for esmirtazapine as of March 2010.
Synonyms: (S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine